CLAIMS

1. An orally administered pharmaceutical formulation comprising tolterodine, and cocoa powder.

2. The formulation according to claim 1, wherein tolterodine comprises its R-isomeric form.

3. The formulation according to claim 1, wherein tolterodine comprises its S-isomeric form.

4. The formulation according to claim 1, wherein tolterodine comprises its racemic form.

5. The formulation according to claim 1, further comprising the tolterodine metabolite (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine.

6. The formulation according to claim 1 further comprising at least one lipid.

7. The formulation according to claim 6, wherein said lipid is selected from cocoa butter, cocoa butter equivalents, cocoa butter substitutes, cocoa butter replacers and cocoa butter improvers, coconut oil, palmkernel oil, palm oil, shea butter, karite butter, illipe butter, mango kernel oil, sal fat, corn oil, sunflower oil, hybrid sunflower oil, soybean oil, rapeseed oil, olive oil, ricebran oil, cottonseed oil, arachis (peanut, groundnut) oil, fish oil, tallow, lard, butterfat and mixtures thereof.

8. The formulation according to claim 7, wherein said lipid is selected from the group consisting of cocoa butter equivalents, cocoa butter substitutes and cocoa butter replacers.

9. The formulation according to claim 1 further comprising at least one buffering agent.

10. The formulation according to claim 9, wherein said buffering agent is selected from the group consisting of carbonates, bicarbonates, acetates, gluconates, glycerophosphates, phosphates or glycinates of sodium, potassium or ammonium, or mixtures thereof.

11. The formulation according to claim 1, further comprising at least one sweetener.

12. The formulation according to claim 11, wherein said at least one or more sweetener is selected from the group consisting of sucrose, aspartame, acesulfame potassium, saccharine, sodium saccharine, cyclamate, glycyrrhizine, thaumatin,

sucralose, neohesperidin dihydrochalcone, alitame, miraculin, monellin, stevside, salts and mixtures thereof.

13. The formulation according to claim1, further comprising at least one emulsifier.

14. The formulation according to claim 1, wherein said at least one emulsifier is selected from the group consisting of

lecithin, poloxamer, polyoxyethylene alkyl ether, polyoxyethylene castor oil derivative, polyoxyethylene sorbitan fatty acid ester, monoglyce- ride, diglyceride and esther thereof, polyoxyethylene stearate, polyglycerolester of fatty acids, sorbitan fatty acid ester, fatty acid, soap of fatty acid, lactylate, sodium lauryl sulfate, latanol, phosphatidylcholine, phosphatidylethanolamine, and mixtures thereof.

15. The formulation according to claim 14, wherein said emulsifier is lecithin.

16. The formulation according to claim 1, further comprising a substance selected from the group consisting of sucrose, fructose, glucose, galactose, lactose, maltose, invert sugar, xylitol, sorbitol, maltitol, mannitol, isomalt, glycerol, polydextrose, starch, or mixtures thereof.

17. The formulation according claim 1, further comprising one or more other agents having an effect against overactive bladder.

18. The formulation according to claim 17, wherein said one or more agents is selected from the group consisting of oxobutynin, emepromium, trospium, propan-etheline, darifenacin and mixtures thereof.

19. A method for treating overactive bladder in a subject comprising administration of a tolterodine-containing orally administered pharmaceutical formulation according to claim 1.